NYSE: CLX · Household & Personal Products

Clorox (CLX) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Clorox (CLX) at $114.12 a share. The stock last closed at $110.17, which puts the model's fair value 3.6% above the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. The Clorox Company.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$114.12midpoint of 2,000 simulations
Last close$110.17NYSE: CLX
Gap to fair value+3.6%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $105.61 to $114.12 (+8.1%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.

What the model makes of itThe price of $110.17 is 3.6% below it: Fairly valued, on a medium evidence grade.

What's nextNext report on 2 Feb 2027. Options prices imply a move of about 11% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give CLX?

The calibrated range for CLX over 63 trading days is $97.68 to $125.02. It sits around the last close, and its width comes from the volatility that CLX's own options imply (36% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $77.47 to $160.76. In 54% of the simulations the fair value came out above the price the model ran on.

$42.36$248.92
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $114.12. Dashed line: the last close, $110.17.

Faircurve Insights · 14 Nov 2026

The Clorox Company (CLX) is a global manufacturer and marketer of both consumer and professional products. It operates through four segments: Health and Wellness, Household, Lifestyle, and International.

Faircurve's model put the fair value at $114.12 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $105.61, so the fair value moved +8.1%. The model's reason: the stock's own trading multiple rose with its price, and the fair value follows it in part, which is most of the move. The calibrated range over 63 trading days is $97.68 to $125.02. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade covers input completeness, the number and agreement of comparable companies, and the spread of outcomes. It does not say whether the fair value is right.

On quality, the model gives the company an overall score of 51 out of 100 against comparable companies. Profitability is the highest factor at 90, with ROIC of 25.3% against a peer median of 19.6%. Earnings quality is 15, with FCF to net income of 0.67x against a peer median of 1.48x. The balance sheet is 19, with net debt to EBITDA of 4.11x against a peer median of 1.49x. The model compares it with e.l.f. Beauty, Inc. (ELF), Church & Dwight Co., Inc. (CHD), Reynolds Consumer Products Inc. (REYN), Kimberly-Clark Corporation (KMB), The Estée Lauder Companies Inc. (EL) and Inter Parfums, Inc. (IPAR).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does CLX report earnings, and how has the stock reacted?

Clorox's next earnings report is scheduled for 2 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 8.5% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. CLX's 30 day implied volatility works out to about 10.5% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CLX's last 8 reports, ignoring direction, was 5.3%.

0%5%10%15%8.4%2.9%5 May '256.2%2.4%31 Jul '257.3%1.8%3 Nov '258.7%4.0%3 Feb '2610.2%8.1%30 Apr '269.2%9.6%3 Aug '268.9%6.6%2 Nov '269.6%10.3%3 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in CLX

5%10%15%20%3 Nov '26 report2 Nov '26 report3 Aug '26 report30 Apr '26 report3 Feb '26 report11% at 16 Nov '2617 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 8% on 17 Nov 2025, reached 14% on 31 Jul 2026 and reads 11% on 16 Nov 2026. The marks are report dates.

How does CLX score on business quality?

Clorox's overall quality score is 51 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.9025.3%ROIC19.6%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).150.67xFCF / net income1.48x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.54-5.4%Revenue growth, trailing1.6%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.571.0%Net buybacks / market value1.3%
Balance sheetNet debt to EBITDA and interest coverage.194.11xNet debt / EBITDA1.49x
StabilityDownside volatility of the EBITDA margin over the last five years.293.1 ptsEBITDA margin downside volatility, 5y1.5 pts

How does CLX compare with similar companies?

The companies in household & personal products closest to Clorox in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
ELF e.l.f. Beauty, Inc.$115.95$113.46-2.1%Fairly valued
CHD Church & Dwight Co., Inc.$114.74$106.62-7.1%Fairly valued
REYN Reynolds Consumer Products Inc.$25.21$24.77-1.7%Fairly valued
KMB Kimberly-Clark Corporation$111.34$126.68+13.8%Fairly valued
EL The Estée Lauder Companies Inc.$108.61$112.89+3.9%Fairly valued
IPAR Inter Parfums, Inc.$134.31$150.32+11.9%Fairly valued
COTY Coty Inc.$4.17$4.59+10.1%Low evidence grade
NWL Newell Brands Inc.$5.85$6.22+6.3%Low evidence grade

What the comparable companies' multiples alone would give for CLX, the peer-implied price, is $126.72 a share on this run. The fair value weighs that against the company's own multiple.

All household & personal products stocks ranked by gap to fair value

Clorox at a glance

The Clorox Company is a global manufacturer and marketer of both consumer and professional products, operating through four distinct segments: Health and Wellness, Household, Lifestyle, and International.

Market value
$13.2B
Sector
Consumer Defensive
Industry
Household & Personal Products
Revenue expected, next twelve months
$7.7B
Consensus revenue growth, next fiscal year
+13.7%
Analysts with estimates
11
Beta to the US market
0.16
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. CLX was among them.

How the fair value is worked out: the model prices Clorox on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for CLX was $105.61. As of 14 Nov 2026 it is $114.12, a change of +8.1%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Clorox's valuation

Is Clorox stock undervalued or overvalued?

On Faircurve's model, CLX reads as Fairly valued as of 14 Nov 2026. The model's fair value is $114.12 a share against a last close of $110.17, a gap of +3.6%.

What is CLX's fair value?

$114.12 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $77.47 to $160.76.

What price range does the model give CLX?

$97.68 to $125.02 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Clorox report earnings next?

The next report is scheduled for 2 Feb 2027. Companies can move their dates.

How much has CLX moved on past earnings reports?

Across its last 8 reports the median two session move was 5.3%, ignoring direction. The largest was +10.3% around the report of 3 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for CLX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on CLX

The model holds no idea open on CLX today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CLX with their outcomes. A free account is enough.

Keep reading